Evogene (EVGN : NASDAQ)
Common Stock
Follow EVGN
EVGN
Evogene
WealthAwesomePerformance
1 Day
+28.70%
1 Week
+2.81%
1 Month
-2.63%
YTD
-33.93%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$5.19M
52W High
$1.26
52W Low
$0.25
P/E Ratio
-
50 Day MA
$0.42
200 Day MA
$0.64
Beta
0.67
Dividend Yield
-
Performance history
EVGN returns since 2026
Evogene has traded since Jun 2026 in our data. Its deepest fall was −61.4% (Aug 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−33.9%
* Partial year (first year of data, or year to date).
$10,000 invested in EVGN
- 2026 (start of our data)$6,607
- All-time high in our data
- $1 on Aug 11, 2026 · now −47.1%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past EVGN? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $0.28 | $0.42 | $0.28 | $0.37 | $0.37 | 2,262,500 |
| 11/9/2026 | $0.27 | $0.30 | $0.27 | $0.29 | $0.29 | 130,285 |
| 11/6/2026 | $0.28 | $0.28 | $0.25 | $0.27 | $0.27 | 405,100 |
| 11/5/2026 | $0.34 | $0.34 | $0.30 | $0.33 | $0.33 | 89,475 |
| 11/4/2026 | $0.35 | $0.36 | $0.35 | $0.36 | $0.36 | 12,600 |
| 11/3/2026 | $0.36 | $0.39 | $0.35 | $0.36 | $0.36 | 23,129 |
| 11/2/2026 | $0.37 | $0.37 | $0.36 | $0.36 | $0.36 | 22,680 |
| 10/30/2026 | $0.38 | $0.38 | $0.37 | $0.37 | $0.37 | 14,700 |
| 10/29/2026 | $0.36 | $0.38 | $0.36 | $0.38 | $0.38 | 13,638 |
| 10/28/2026 | $0.36 | $0.39 | $0.35 | $0.37 | $0.37 | 40,402 |
Analyst Price Targets
Based on 1 analyst covering EVGN · as of Oct 5, 2026
Wall Street analysts forecast EVGN stock price to rise 186.7% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$2.15
+186.7% Upside
Current Price
US$0.75
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EVGN's historical volatility
30-Day Vol
113.2%
Annualized
90-Day Vol
115.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.35 | US$0.24 – US$0.52 |
| 60 trading days | US$0.33 | US$0.19 – US$0.57 |
| 90 trading days | US$0.31 | US$0.16 – US$0.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Financials
- Revenue (TTM)
- $1.66M
- EBITDA
- $-13.87M
- Profit Margin
- 0.00%
- ROE (TTM)
- -182.75%
- EPS (Diluted)
- -1.55
- Book Value
- -0.24
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About EVGN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Free with a Wealth Awesome account
Keep analysing EVGN, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.